Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
AnHeart Therapeutics acquisition by Nuvation Bio
We are advising AnHeart Therapeutics on the acquisition
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Auna $360 million U.S. IPO
We advised Auna on its U.S. IPO and NYSE listing
Haleon $3.1 billion secondary offering
The shares are listed on the NYSE
Smith+Nephew $1 billion notes offering
We advised the issuer on the SEC-registered offering
Avid Bioservices $160 million convertible senior notes offering
The convertible notes are due 2029
REGENXBIO $140 million stock and pre-funded warrants offering
The stock is listed on the Nasdaq Global Select Market
iRhythm Technologies $661.25 million convertible senior notes offering
The 1.5% convertible senior notes are due 2029
Roche Holdings $3.875 billion notes offering
We advised Roche on the Rule 144A / Regulation S offering comprising four tranches of notes
Tandem Diabetes Care $316.25 million convertible senior notes offering
The 1.5% convertible senior notes are due 2029